Burimamide

Burimamide

Names
IUPAC name 1-[4-(1H-imidazol-5-yl)butyl]-3-methylthiourea
Identifiers
CAS Number	34970-69-9
ChEMBL	ChEMBL12160
ChemSpider	2297780
Jmol interactive 3D	Image
KEGG	C07448
PubChem	3032915
UNII	TN5A4OD2TV
InChI InChI=1S/C9H16N4S/c1-10-9(14)12-5-3-2-4-8-6-11-7-13-8/h6-7H,2-5H2,1H3,(H,11,13)(H2,10,12,14) Key: HXRBAVXGYZUSED-UHFFFAOYSA-N InChI=1/C9H16N4S/c1-10-9(14)12-5-3-2-4-8-6-11-7-13-8/h6-7H,2-5H2,1H3,(H,11,13)(H2,10,12,14) Key: HXRBAVXGYZUSED-UHFFFAOYAJ
SMILES S=C(NC)NCCCCc1cncn1
Properties
Chemical formula	C9H16N4S
Molar mass	212.32 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
verify (what is  ?)
Infobox references

Burimamide is an antagonist at the H₂ and H₃ histamine receptors. It is largely inactive as an H₂ antagonist at physiological pH,^[1] but its H₃ affinity is 100x higher. It is a thiourea derivative.

Burimamide was first developed by scientists at Smith, Kline & French (SK&F; now GlaxoSmithKline) in their intent to develop a histamine antagonist for the treatment of peptic ulcers.^[2] The discovery of burimamide ultimately led to the development of cimetidine (Tagamet).^[2]

See also

• Metiamide
• Cimetidine

References

1. Clayden, Jonathan; Greeves, Nick; Warren, Stuart; Wothers, Peter (2001). Organic Chemistry (1st ed.). Oxford University Press. p. 205. ISBN 978-0-19-850346-0.
2. "Tagamet^®: Discovery of Histamine H₂-receptor Antagonists". National Historic Chemical Landmarks. American Chemical Society. Retrieved June 25, 2012.